Neovasc’s Reducer Shows Promise For Refractory Angina
This article was originally published in The Gray Sheet
In a small but sham-controlled trial Neovasc’s balloon-expandable implant significantly improved symptoms and quality of life in patients with refractory angina who are not candidates for other revascularization procedures. Reducer works by increasing pressure in the coronary sinus.
You may also be interested in...
Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.
In this wide-ranging interview, lawyer Philip Desjardins talks about regulatory issues from AI to LDTs – as well as the passion for patient health that keeps him in the medtech arena.